Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$58.24M
EBITDA Margin
-99843.01%
TTM Avg
-70984.01%
3Y Avg
-70984.01%
5Y Avg
-70984.01%
Market Cap
$55.21M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$58.99M
EBITDA Margin
-3226.05%
TTM Avg
-3226.05%
3Y Avg
-3226.05%
5Y Avg
-3226.05%
Market Cap
$59.91M
EBITDA Margin
-753.96%
TTM Avg
-753.96%
3Y Avg
-753.96%
5Y Avg
-753.96%
Market Cap
$53.63M
EBITDA Margin
-5927.25%
TTM Avg
-3470.39%
3Y Avg
-2050.54%
5Y Avg
-1465.25%
Market Cap
$53.46M
EBITDA Margin
-40.55%
TTM Avg
-30.41%
3Y Avg
-34.23%
5Y Avg
-32.87%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OKYO Pharma Limited (OKYO) | $56.78M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.42M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $58.24M | -99843.01% | -70984.01% | -70984.01% | -70984.01% |
| PDS Biotechnology Corporation (PDSB)vs › | $55.21M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.99M | -3226.05% | -3226.05% | -3226.05% | -3226.05% |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.91M | -753.96% | -753.96% | -753.96% | -753.96% |
| ImageneBio Inc (IMA)vs › | $53.63M | -5927.25% | -3470.39% | -2050.54% | -1465.25% |
| Aldeyra The (ALDX)vs › | $53.20M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $53.46M | -40.55% | -30.41% | -34.23% | -32.87% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.32M | -89640.62% | -44862.17% | -44862.17% | -44862.17% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
